London’s Al Saqi Books Closes Its Doors End of December

London’s Al Saqi Books Closes Its Doors End of December
TT

London’s Al Saqi Books Closes Its Doors End of December

London’s Al Saqi Books Closes Its Doors End of December

Sad news! London’s Al Saqi Books, which served as a cultural center for 44 years, announced closing its doors on December 31.

The general situation, long lockdowns, and the increasing costs of papers and shipping have aggravated the crisis of libraries, publishers, and everything related to books. Like many victims affected in these fragile professions, especially those working in the field of Arabic books, this esteemed library, which played a central role for Arabs and non-Arabs interested in Arabic books in the UK, has decided to put an end to its journey.

“The various lockdowns and the ensuing breakdown of supply chains negatively impacted many independent businesses, such as ours. But as a specialist Arab-world bookseller sourcing our stock from the Middle East and North Africa, we also had to contend with sharp increases in Arabic-language book prices, shipping charges and exchange rates,” owner Salwa Gaspard told the Bookseller Magazine.

“For me, Al Saqi is more than just a library. I grew up in Al Saqi, my sister and I spent hours playing around books. I was honored to work in it with my parents. We will miss the library but we are looking forward to the next chapter in Al Saqi history from our new location in western London. We are thrilled to bring the best new and classic books from the Arab world to the United Kingdom and other countries within the coming years,” saddened Lyn Gaspard said about the library that her parents co-founded with Mai Ghoussoub.

Al Saqi Books, London, was established in 1979 by friends Mai Ghoussoub and Andre Gaspard, it was the first Arabic library in the UK. In 1982, they opened a special section in the library for English books about the Middle East, and then launched English publishing in 1983. Al Saqi started Arabic publishing in 1987 supported by its strong ties with its readers and other London-based publishers.
Dar Al Saqi publishing was founded in Beirut, in 1991, pledging to promote intellectual innovation and the renaissance of Arabic culture.

It acted as a bridge between the Arabic and western cultures by encouraging dialogue, introducing the western culture to the Arab readers, and showcasing causes that concern the Arabic society in the west.

The Arabic publishing house, which also established “Al Saqi Kids and Youth” in 2012, won many prizes. After its closure in London, Al Saqi is still alive and struggling for survival in Beirut.

“Although Al Saqi is closing its doors in London, its heritage will continue with its two independent publishing houses: Dar Al Saqi for Arabic Publishing (Beirut), and Saqi Books for English publishing in London,” Dar Al Saqi said in a statement.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”